Application of AsO combined with TSA in preparing medicament for inducing leukocythemia HL60 cell to convert from portion differentiation to apoptosis

Application of AsO combined with TSA in preparing medicament for inducing leukocythemia HL60 cell to convert from portion differentiation to apoptosis

The invention discloses the application of a As2O3 combined TSA in preparing drugs to induce the change of leukemia HL60 cells from partial differentiation to apoptosis. The concentration of the drug used to induce the change of leukemia HL60 cells from partial differentiation to apoptosis is: 0.5 t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: LIN RUXIANG, YANG WEIHUA, TANG TIANHUA, REN XIA, REN HAIQUAN, WEN PEIE, LI ZHIHUI, JIANG GUOSHENG
Format: Patent
Sprache:chi ; eng
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The invention discloses the application of a As2O3 combined TSA in preparing drugs to induce the change of leukemia HL60 cells from partial differentiation to apoptosis. The concentration of the drug used to induce the change of leukemia HL60 cells from partial differentiation to apoptosis is: 0.5 to 1.0 Mu M of As2O3; 0.1 Mu M to 0.2 Mu M of TSA. In the aspect of drug combination to induce apoptosis, the drug laid basis for clinical drug combination therapy to induce leukaemia apoptosis.